Rhodia receives
Rhodia Pharma Solutions has received a
Rhodia Pharma Solutions has received a £1.8m grant phased over three years from Scottish Enterprise's R&D Plus programme. The grant will help fund a £4.5m upgrade of a production unit at the company's active pharmaceutical ingredients and intermediates facility in Annan, Scotland.
The unit is now involved with the manufacture of a cancer drug currently in clinical trials in the US.
'The Annan investment is part of a plan initiated a few years ago to upgrade the capability of our UK pharmaceutical development and scale-up facilities,' said Nick Green, president of Rhodia Pharma Solutions. 'The Annan facility is ideally suited to help Rhodia address the unmet needs of the market.'
Rhodia is the first company to benefit from the new R&D Plus scheme, which has gained approval from the European Union.